Trial results raise hope for dengue fever vaccineBMJ 2015; 350 doi: https://doi.org/10.1136/bmj.h141 (Published 09 January 2015) Cite this as: BMJ 2015;350:h141
- Jacqui Wise
A tetravalent dengue vaccine has shown efficacy against dengue fever and severe dengue fever and led to fewer hospitalisations in a randomised, blinded, placebo controlled trial.
The efficacy trial, reported in the New England Journal of Medicine,1 was carried out in five Latin American countries in which dengue is endemic. A total of 20 869 healthy children aged 9 to 16 were randomly assigned in a 2:1 ratio to receive either three injections of recombinant, live attenuated tetravalent dengue vaccine (CYD-TDV) or placebo.
Dengue is transmitted by mosquitoes …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial